Equities analysts expect that CytomX Therapeutics Inc (NASDAQ:CTMX) will announce sales of $15.11 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for CytomX Therapeutics’ earnings. The lowest sales estimate is $8.00 million and the highest is $24.47 million. CytomX Therapeutics posted sales of $21.34 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 29.2%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 14th.

According to Zacks, analysts expect that CytomX Therapeutics will report full year sales of $69.46 million for the current fiscal year, with estimates ranging from $53.50 million to $90.48 million. For the next fiscal year, analysts anticipate that the company will report sales of $51.61 million, with estimates ranging from $32.52 million to $61.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.22. The business had revenue of $29.49 million during the quarter, compared to analysts’ expectations of $13.59 million. CytomX Therapeutics had a negative return on equity of 73.62% and a negative net margin of 111.27%.

Several brokerages have weighed in on CTMX. Cantor Fitzgerald began coverage on CytomX Therapeutics in a report on Monday, May 13th. They issued an “overweight” rating and a $21.00 price objective for the company. Nomura dropped their price objective on CytomX Therapeutics to $22.00 in a report on Monday, May 13th. BidaskClub raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 7th. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, Mizuho began coverage on CytomX Therapeutics in a research note on Wednesday, June 12th. They issued a “buy” rating and a $16.00 price target on the stock. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. CytomX Therapeutics currently has an average rating of “Buy” and an average target price of $20.72.

NASDAQ CTMX traded up $0.17 during midday trading on Wednesday, hitting $12.25. The company had a trading volume of 20,034 shares, compared to its average volume of 459,546. The stock has a market cap of $562.76 million, a P/E ratio of -6.11 and a beta of 0.64. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.22. The business has a 50-day moving average of $10.69. CytomX Therapeutics has a twelve month low of $8.94 and a twelve month high of $27.20.

Institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc increased its stake in shares of CytomX Therapeutics by 18.6% in the 4th quarter. Legal & General Group Plc now owns 8,342 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 1,306 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of CytomX Therapeutics by 84,072.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,259 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 9,248 shares during the last quarter. Deltec Asset Management LLC bought a new position in shares of CytomX Therapeutics in the 1st quarter valued at $129,000. Metropolitan Life Insurance Co. NY increased its stake in shares of CytomX Therapeutics by 376.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 10,650 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of CytomX Therapeutics by 21.5% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,700 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 2,600 shares during the last quarter. Institutional investors own 81.83% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Recommended Story: Commodities

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.